• Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications
• New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America
  • Combined capabilities across Bristol, St. Paul and Minneapolis support customers from discovery through commercial manufacturing

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.